A week after Pfizer, the Moderna laboratory announced that, according to preliminary results, its vaccine against Covid-19 was 94.5% effective. According to the American press, the tests could be finalized and an authorization for emergency use requested in the coming weeks.
The United States could have two vaccines against the novel coronavirus by the end of the year, reports the Washington Post. The American laboratory Moderna indeed announced this Monday, November 16 that, according to preliminary results, its vaccine against Covid-19 had an efficacy rate of 94.5%, a week after a similar announcement from Pfizer laboratories and BioNTech.
This vaccine has been tested on a sample of 30,000 people. According to STAT, 95 cases of contamination were detected in the patients who received a placebo, against five cases for those who received the Moderna vaccine.
The laboratory, which signed a $ 1.525 billion contract with the US government to supply the US with 100 million doses of its vaccine, also announced that it would file an application for authorization of the vaccine in the coming weeks. emergency use with the Food and Drug Administration – the US agency